Vila Isabelle K, Song Su Jung, Song Min Sup
Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Soonchunhyang Institute of Medi-bio Science, Soonchunhyang University, Cheonan-si, Chungcheongnam-do, Republic of Korea.
Mol Cell Oncol. 2017 Mar 17;4(3):e1304846. doi: 10.1080/23723556.2017.1304846. eCollection 2017.
() is upregulated in human cancers. We have demonstrated that genetic deletion or pharmacological blockade of reduces tumorigenesis through inhibiting the mammalian target of rapamycin complex 1-hypoxia-inducible factor 1-α pathway. Critically, UBE2O targets adenosine monophosphate (AMP)-activated protein kinase-α 2 (AMPKα2) for ubiquitination and degradation. We thus suggest the UBE2O-AMPKα2 axis as a potential therapeutic target for cancer.
()在人类癌症中上调。我们已经证明,基因缺失或药物阻断 通过抑制雷帕霉素复合物1-缺氧诱导因子1-α途径的哺乳动物靶点来减少肿瘤发生。至关重要的是,UBE2O将腺苷单磷酸(AMP)激活的蛋白激酶-α 2(AMPKα2)靶向泛素化和降解。因此,我们认为UBE2O-AMPKα2轴是癌症的潜在治疗靶点。